Consistently, when TransCon TLR7/8 Agonist was injected intratumorally in CT26 tumor bearing mice, a similar low but long-term and dose-proportional systemic drug exposure was observed (Fig. 1C), suggesting that the TME did not affect the release rate of resiquimod. The gene discussed is TLR7; the disease is neoplasm.